# Noetik **Source:** https://geo.sig.ai/brands/noetik **Vertical:** Healthcare Tech **Subcategory:** AI Cancer Biology & Drug Discovery **Tier:** Emerging **Website:** noetik.ai **Last Updated:** 2026-04-14 ## Summary Noetik raised 2M and signed a 0M GSK licensing deal to build cancer biology foundation models on multi-omic data, uncovering drug targets invisible to conventional tools (2022, SF). ## Company Overview Noetik is a San Francisco-based AI-native biotechnology company founded in 2022 with the mission of decoding cancer biology at molecular resolution using foundation models trained on multi-omic data. The company was founded on the thesis that the biological complexity underlying cancer — the interactions between tumor cells, the immune system, the tumor microenvironment, and genomic variation — exceeds what human researchers or conventional computational tools can fully model, and that large-scale AI trained on comprehensive biological datasets can discover drug targets and patient stratification strategies that would otherwise remain hidden. Noetik builds cancer biology foundation models that learn the language of cellular systems from massive datasets of genomic, transcriptomic, and proteomic measurements.\n\nNoetik's platform applies its foundation models to drug discovery programs, with a focus on identifying novel targets in difficult-to-treat cancers and predicting which patient populations are most likely to respond to specific therapeutic mechanisms. The models are designed to generate hypotheses at a speed and scale that dramatically compresses the early discovery timeline, enabling the company and its partners to explore vastly more biological hypotheses per year than conventional approaches allow. Noetik's scientific platform is built to be partnered as well as proprietary — the company licenses its cancer biology AI capabilities to pharmaceutical companies seeking to accelerate and de-risk their early discovery pipelines.\n\nNoetik has raised $62 million in total funding and secured a $50 million licensing deal with GSK, one of the world's largest pharmaceutical companies, validating both the scientific quality of its foundation models and the commercial interest from major pharma in AI-native biology platforms. The GSK deal provides both capital and a prestigious scientific partnership that elevates Noetik's credibility across the drug discovery ecosystem. As AI biology becomes a defining competitive dimension in pharmaceutical R&D, Noetik's cancer-focused foundation models and demonstrated ability to attract top-tier pharma partnerships position it as an emerging leader in AI-driven oncology drug discovery. ## Frequently Asked Questions ### What does Noetik do? AI foundation models simulating cancer tumor biology for immunotherapy drug discovery. ### What is the GSK deal? $50M for nonexclusive license to NSCLC and colorectal cancer models (early 2026). ### How much has Noetik raised? $62M: $14M seed (2023) + $40M Series A (2024, Polaris Partners). ### Where is Noetik based? San Francisco. Founded 2022. ### What is the scientific basis of Noetik's tumor biology simulation? Noetik's AI foundation models are trained on multi-omics cancer data — genomics, transcriptomics, proteomics, and spatial biology data from patient tumors — to learn the molecular rules governing tumor behavior and immune system interactions. The model simulates how cancer cells respond to immunotherapy approaches by predicting the tumor's evolutionary and immunological response to treatment, enabling researchers to identify which patients and which drug mechanisms are most likely to produce durable responses. ### What is the significance of Noetik's $50M GSK licensing deal? GSK's $50M nonexclusive license for Noetik's NSCLC (non-small cell lung cancer) and colorectal cancer tumor biology models validates Noetik's simulation capability at one of the world's largest pharmaceutical R&D budgets. GSK will use the models to accelerate its oncology pipeline by simulating tumor response before and during clinical trials — reducing the risk of late-stage clinical failures for drugs that look promising in early testing but fail in heterogeneous patient populations. ### How does Noetik's AI differ from traditional cancer drug screening approaches? Traditional cancer drug screening uses cell culture and mouse models — systems with fundamental limitations in predicting human tumor response. Noetik's AI simulation is trained on actual human patient data and captures the complexity of tumor heterogeneity, immune evasion mechanisms, and clonal evolution that in vitro and mouse models miss. The simulation approach enables much larger virtual screening of drug-target combinations than laboratory models allow. ### What oncology indications beyond NSCLC and colorectal cancer is Noetik pursuing? While Noetik's GSK deal focuses on NSCLC and colorectal cancer, the company's platform is designed to be applicable across solid tumor types where immunotherapy is a treatment approach. The company's $62M in funding provides runway to build additional cancer indication models. Pancreatic cancer, melanoma, and bladder cancer are among the solid tumor types with significant immunotherapy development activity where simulation models could have high value. ## Tags b2b, healthtech, saas --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*